Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Financials
  5. Interim Results

Interim Results

Thumbnail
May 03, 2022

Biogen says goodbye to Vounatsos and remaining Aduhelm hopes

The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?

Thumbnail
August 24, 2021

Big medtech convalesces after Covid-19

What goes down must come up.

Article image
Vantage logo
May 04, 2021

Comirnaty on track to make sales history

Article image
Vantage logo
October 15, 2020

For Roche the pandemic giveth and taketh away

Article image
Vantage logo
August 25, 2020

Orthopaedics companies’ nightmare quarter

The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.

Article image
Vantage logo
July 31, 2020

Gilead unleashes the remdesivir blockbuster bulls

Article image
Vantage logo
July 30, 2020

Covid-19 deals different fates in the Parp world for Glaxo and Astra

Article image
Vantage logo
July 23, 2020

A poor quarter for Roche leads to muted expectations

Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.

Article image
Vantage logo
May 21, 2020

Covid-19 takes a toll on medtech’s first quarter

Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.

Article image
Vantage logo
May 18, 2020

Covid-19 excitement masks Sorrento’s disastrous capital structure

Article image
Vantage logo
May 13, 2020

Big Pharma remains bullish in the face of Covid-19

So far so good, as much of pharma shrugs off the full-year impact of Covid-19.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.